Very Brief Exposure for Social Anxiety Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new approach called Very Brief Exposure (VBE) therapy to assist teens and young adults with social anxiety disorder (SAD). Researchers aim to determine how brief exposure to various facial expressions affects brain activity and helps regulate emotions and attention. Participants will view images while undergoing brain scans to measure fear responses and brain activity related to emotion control. Individuals aged 16 to 22 with diagnosed social anxiety disorder may be suitable for this study. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could lead to new treatments for social anxiety disorder.
Will I have to stop taking my current medications?
Yes, participants cannot be on any current psychoactive medication to join this trial.
What prior data suggests that this method is safe for youth with social anxiety disorder?
Research has shown that exposure therapy is generally safe and effective in reducing anxiety symptoms. In several studies, participants experienced a significant decrease in anxiety levels. For example, one study found that most participants felt comfortable with the treatment, with only a few experiencing discomfort. Additionally, early findings suggest that exposure therapy, particularly when involving real-life social situations, outperforms some traditional therapy methods. Overall, exposure therapy has a strong track record of safety and effectiveness in treating social anxiety.12345
Why are researchers excited about this trial?
Unlike the standard treatments for social anxiety disorder, such as cognitive-behavioral therapy (CBT) and medications like SSRIs, Very Brief Exposure focuses on quick, targeted exposure to social cues. Participants view images of diverse facial expressions on a computer screen, which helps them rate and process social information differently. Researchers are excited about this method because it offers a non-invasive, rapid approach that could potentially reduce anxiety without the need for long-term medication or extensive therapy sessions.
What evidence suggests that Very Brief Exposure is effective for social anxiety disorder?
Research shows that very brief exposure (VBE) therapy, which participants in this trial will experience, can effectively reduce social anxiety. Studies have demonstrated that short exercises involving imagined social situations can help lower anxiety. For example, several studies found significant reductions in anxiety symptoms after using exposure therapy. One study noted that these brief exercises were especially helpful for anxiety related to social interactions. Overall, exposure therapy has a strong history of easing symptoms of social anxiety disorder, offering hope for those seeking relief.16789
Who Is on the Research Team?
Bradley S. Peterson, MD
Principal Investigator
Children's Hospital Los Angeles
Are You a Good Fit for This Trial?
This trial is for transition-age youth with social anxiety disorder (SAD). Participants will be involved in an interview and MRI scans where they'll rate images of facial expressions. Key eligibility details are not provided, so interested individuals should inquire about specific inclusion and exclusion criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Image Exposure
Participants will see various images of facial expressions on a computer screen and provide various rating scores about them.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Very Brief Exposure
Very Brief Exposure is already approved in United States for the following indications:
- Post-traumatic stress disorder (PTSD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Los Angeles
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator